To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06869473
Title Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)>/=1=/<19. (AVEC-119)
Acronym AVEC-119
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Gruppo Oncologico del Nord-Ovest
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA

Facility Status City State Zip Country Details
Irccs Humanitas Research Hospital NOT_YET_RECRUITING Rozzano Milano 20089 Italy Details
Ospedale Oncologico "A. Businco" ARNAS BROTSU NOT_YET_RECRUITING Cagliari 09121 Italy Details
Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico-S. Marco NOT_YET_RECRUITING Catania 95123 Italy Details
Azienda Ospedaliero-Universitaria Careggi RECRUITING Firenze 50134 Italy Details
Fondazione IRCCS Istituto Nazionale dei Tumori (INT) di Milano RECRUITING Milano 20133 Italy Details
Irccs Fondazione G. Pascale RECRUITING Napoli 80131 Italy Details
AOU Luigi Vanvitelli NOT_YET_RECRUITING Napoli 80138 Italy Details
Azienda Ospedaliero-Universitaria Sant'Andrea NOT_YET_RECRUITING Roma 00189 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field